Zoetis ZTS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| International | $1.15B+16.6% | $1.12B+7.9% | $1.06B+3.3% | $1.07B+3.4% | $985M-2.2% | |
| U.S. | $1.09B-7.9% | $1.24B-1.7% | $1.32B-1.8% | $1.36B+3.7% | $1.18B+1.7% | |
| Gross Profit by Business | ||||||
| International | $815M+18.1% | $756M+7.5% | $724M+3.4% | $756M+9.1% | $690M-0.6% | |
| U.S. | $896M-8.9% | $1.02B-0.5% | $1.1B+1.1% | $1.15B+6.7% | $984M+4.0% | |
| Nonoperating Income (Expense) by Business | ||||||
| International | -$1M— | $3M+50.0% | -$1M0.0% | $0— | $0— | |
| U.S. | $0— | $0+100% | $0— | $0— | $0— | |
| Operating expenses by Business | ||||||
| International | $175M+7.4% | $183M+1.7% | $167M+6.4% | $173M-1.1% | $163M+2.5% | |
| U.S. | $199M-2.9% | $193M-9.0% | $201M+1.0% | $218M+6.9% | $205M+7.9% | |
| Income before provision for taxes on income by Business | ||||||
| International | $639M+21.3% | $574M+9.8% | $556M+2.6% | $583M+12.5% | $527M-1.5% | |
| Other business activities | -$141M-6.0% | -$159M-5.3% | -$140M-2.2% | -$134M+5.6% | -$133M-0.8% | |
| U.S. | $697M-10.5% | $830M+1.3% | $899M+1.1% | $930M+6.7% | $779M+3.0% | |
| Gross margin, percentage by Business | ||||||
| International | 70.9%+0.8pp | —— | 68.6%0.0pp | 70.7%+3.7pp | 70.1%+1.2pp | |
| U.S. | 82.2%-1.0pp | —— | 83.2%+2.4pp | 84.7%+2.4pp | 83.2%+1.9pp | |
| Depreciation and amortization expense by Business | ||||||
| International | $26M+13.0% | $26M+13.0% | $26M+4.0% | $25M0.0% | $23M0.0% | |
| Other business activities | $13M+18.2% | $13M-7.1% | $14M+55.6% | $13M+18.2% | $11M+22.2% | |
| U.S. | $23M0.0% | $23M+15.0% | $25M+25.0% | $22M+4.8% | $23M-4.2% | |
| Cost of Sales by Business | ||||||
| International | $334M+13.2% | $365M+8.6% | $331M+3.1% | $314M-8.2% | $295M-5.8% | |
| U.S. | $194M-2.5% | $213M-7.0% | $222M-14.0% | $208M-10.3% | $199M-8.3% | |
| Revenue by Product | ||||||
| Animal health diagnostics | $117M+12.5% | $111M+11.0% | $110M+8.9% | $110M+6.8% | $104M+26.8% | |
| Anti-infectives | $241M+1.3% | $284M+1.1% | $284M+3.6% | $219M-17.0% | $238M-15.3% | |
| Cattle | $392M+15.0% | $415M+4.0% | $399M+2.0% | $320M-8.6% | $341M-12.8% | |
| Contract manufacturing & human health | $23M-23.3% | $30M+42.9% | $23M+9.5% | $34M+88.9% | $30M+50.0% | |
| Dermatology | $349M-7.9% | $429M+1.9% | $472M+4.2% | $463M+10.8% | $379M+4.4% | |
| Dogs and Cats | $1.44B-2.3% | —— | $1.59B+2.3% | $1.72B+8.5% | $1.48B+6.7% | |
| Fish | $66M+20.0% | $81M+24.6% | $78M+11.4% | $74M+19.4% | $55M+22.2% | |
| Horses | $76M+18.8% | $6.08B+4.8% | $66M+13.8% | $72M+5.9% | $64M-3.0% | |
| Other Non Pharmaceuticals | $66M-7.0% | $70M+7.7% | $64M+3.2% | $63M-3.1% | $71M+16.4% | |
| Other pharmaceutical | $158M0.0% | $188M+4.4% | $178M+5.3% | $172M+12.4% | $158M+1.3% | |
| Pain and sedation | $203M-1.9% | $209M-3.7% | $204M-6.8% | $217M-1.8% | $207M+6.7% | |
| Parasiticides | $586M+2.4% | $542M+4.4% | $564M+6.4% | $673M+12.2% | $572M+13.5% | |
| Poultry | $118M+11.3% | $117M0.0% | $106M-23.7% | $103M-22.0% | $106M-23.7% | |
| Sheep and other | $21M+5.0% | $18M+5.9% | $31M+14.8% | $22M+10.0% | $20M+11.1% | |
| Swine | $123M+17.1% | $125M-2.3% | $111M-15.3% | $119M-8.5% | $105M-17.3% | |
| Vaccines | $519M+18.2% | $512M+10.8% | $496M+6.0% | $504M+13.3% | $439M-2.9% | |
| Revenue by Geography | ||||||
| Australia | $89M+12.7% | $84M+5.0% | $87M+4.8% | $83M0.0% | $79M+8.2% | |
| Brazil | $90M+11.1% | $112M-0.9% | $100M-1.0% | $93M-6.1% | $81M-19.8% | |
| Canada | $73M+4.3% | $80M+6.7% | $70M+6.1% | $73M-2.7% | $70M+14.8% | |
| Chile | $38M+8.6% | $40M+33.3% | $29M-6.5% | $36M+16.1% | $35M+12.9% | |
| China | $63M+14.5% | $50M-23.1% | $45M-26.2% | $72M+5.9% | $55M-27.6% | |
| France | $37M-5.1% | $52M+15.6% | $40M+11.1% | $33M-2.9% | $39M-4.9% | |
| Germany | $59M+7.3% | $65M+10.2% | $62M+8.8% | $58M0.0% | $55M+7.8% | |
| Italy | $39M+30.0% | $35M+2.9% | $35M+12.9% | $38M+5.6% | $30M+7.1% | |
| Japan | $35M+9.4% | $39M+2.6% | $34M+3.0% | $45M+15.4% | $32M-13.5% | |
| Mexico | $48M+37.1% | $44M+10.0% | $41M+5.1% | $38M-17.4% | $35M-20.5% | |
| Other developed markets | $169M+27.1% | $182M+20.5% | $164M+10.8% | $162M+17.4% | $133M+4.7% | |
| Other emerging markets | $291M+22.3% | $212M+8.7% | $228M+3.6% | $225M+1.4% | $238M+4.4% | |
| Spain | $40M+37.9% | $37M+23.3% | $38M+8.6% | $37M+12.1% | $29M-9.4% | |
| Total geographical area | $2.24B+3.3% | $2.36B+2.7% | $2.38B+0.4% | $2.43B+3.5% | $2.17B-0.1% | |
| United Kingdom | $78M+5.4% | $89M+6.0% | $82M+2.5% | $77M+5.5% | $74M-3.9% | |
| United States | $1.09B-7.9% | $1.24B-1.7% | $1.32B-1.8% | $1.36B+3.7% | $1.18B+1.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zoetis break its business down?
- Zoetis (ZTS) reports revenue by business across 2 parts — International and U.S.. Each is extracted from the segment footnotes and tracked over time.
- Where does Zoetis's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zoetis's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
